296 related articles for article (PubMed ID: 16926601)
21. The effect of maintenance immunosuppression medication on the change in kidney allograft function.
Gill JS; Tonelli M; Mix CH; Johnson N; Pereira BJ
Kidney Int; 2004 Feb; 65(2):692-9. PubMed ID: 14717943
[TBL] [Abstract][Full Text] [Related]
22. Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus-based regimens.
Wlodarczyk Z; Walaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradszky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Kalmar KN; Hickey D
Transpl Int; 2005 Feb; 18(2):157-62. PubMed ID: 15691267
[TBL] [Abstract][Full Text] [Related]
23. Pediatric renal transplantation with mycophenolate mofetil-based immunosuppression without induction: results after three years.
Jungraithmayr T; Staskewitz A; Kirste G; Böswald M; Bulla M; Burghard R; Dippell J; Greiner C; Helmchen U; Klare B; Klaus G; Leichter HE; Mihatsch MJ; Michalk DV; Misselwitz J; Plank C; Querfeld U; Weber LT; Wiesel M; Tönshoff B; Zimmerhackl LB;
Transplantation; 2003 Feb; 75(4):454-61. PubMed ID: 12605109
[TBL] [Abstract][Full Text] [Related]
24. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
Fisher RA; Stone JJ; Wolfe LG; Rodgers CM; Anderson ML; Sterling RK; Shiffman ML; Luketic VA; Contos MJ; Mills AS; Ferreira-Gonzalez A; Posner MP
Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
[TBL] [Abstract][Full Text] [Related]
25. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
[TBL] [Abstract][Full Text] [Related]
26. Improved solitary pancreas transplant graft survival in the modern immunosuppressive era.
Odorico JS; Becker YT; Groshek M; Werwinski C; Becker BN; Pirsch JD; Sollinger HW
Cell Transplant; 2000; 9(6):919-27. PubMed ID: 11202579
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients.
Böhler T; Canivet C; Galvani S; Therville N; Salvayre R; Negre-Salvayre A; Durand D; Thomsen M; Rostaing L; Kamar N
Int Immunopharmacol; 2008 May; 8(5):769-73. PubMed ID: 18387521
[TBL] [Abstract][Full Text] [Related]
28. Mycophenolate mofetil/tacrolimus/single-shot versus azathioprine/cyclosporine/ATG in pancreas-kidney transplantation: results of a prospective randomized single-center study.
Büsing M; Martin D; Schulz T; Heimes M; Klempnauer J; Kozuschek W
Transplant Proc; 1998 Mar; 30(2):516-7. PubMed ID: 9532155
[No Abstract] [Full Text] [Related]
29. Impact of maintenance immunosuppressive regimens--balance between graft protective suppression of immune functions and a near physiological immune response.
Weimer R; Deisz S; Dietrich H; Renner F; Bödeker RH; Daniel V; Kamali-Ernst S; Ernst W; Padberg W; Opelz G
Transpl Int; 2011 Jun; 24(6):596-609. PubMed ID: 21401729
[TBL] [Abstract][Full Text] [Related]
30. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.
Remuzzi G; Cravedi P; Costantini M; Lesti M; Ganeva M; Gherardi G; Ene-Iordache B; Gotti E; Donati D; Salvadori M; Sandrini S; Segoloni G; Federico S; Rigotti P; Sparacino V; Ruggenenti P
J Am Soc Nephrol; 2007 Jun; 18(6):1973-85. PubMed ID: 17460145
[TBL] [Abstract][Full Text] [Related]
31. Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion.
Thervet E; Morelon E; Ducloux D; Bererhi L; Noël LH; Janin A; Bedrossian J; Puget S; Chalopin JM; Mihatsch M; Legendre C; Kreis H
Clin Transplant; 2000 Dec; 14(6):561-6. PubMed ID: 11127309
[TBL] [Abstract][Full Text] [Related]
32. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
[TBL] [Abstract][Full Text] [Related]
33. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
[TBL] [Abstract][Full Text] [Related]
34. Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation.
Busque S; Shoker A; Landsberg D; McAlister V; Halloran P; Shapiro J; Peets J; Schulz M
Transplant Proc; 2001; 33(1-2):1266-7. PubMed ID: 11267285
[No Abstract] [Full Text] [Related]
35. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
Bunnapradist S; Daswani A; Takemoto SK
Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
[TBL] [Abstract][Full Text] [Related]
36. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
[TBL] [Abstract][Full Text] [Related]
37. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients.
Kim SJ; Lee KW; Lee DS; Lee HH; Lee SK; Kim B; Huh WS; Oh HY; Joh JW
Transplant Proc; 2004 Sep; 36(7):2098-100. PubMed ID: 15518759
[TBL] [Abstract][Full Text] [Related]
38. Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients?
Johnson DW; Nicol DL; Purdie DM; Preston JM; Brown AM; Hawley CM; Campbell SB; Wall D; Griffin AD; Isbel NM
Transplantation; 2002 Apr; 73(7):1158-63. PubMed ID: 11965051
[TBL] [Abstract][Full Text] [Related]
39. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.
Su VCh; Greanya ED; Ensom MH
Ann Pharmacother; 2011 Feb; 45(2):248-57. PubMed ID: 21304036
[TBL] [Abstract][Full Text] [Related]
40. [Replacement of mycophenolate mofetil with azathioprine in patients with renal transplants].
Hrvacević R; Ignjatović Lj; Butorajac J; Vavić N; Drasković-Pavlović B; Dujić A; Marić M
Vojnosanit Pregl; 2001; 58(3):255-8. PubMed ID: 11548550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
